Pair Of Cancer-Focused Biotechs Launch IPOs Totaling $300M
Two cancer-focused biotechnology firms on Monday set price ranges for initial public offerings projected to raise a combined $300 million under the guidance of four law firms, continuing a wave of...To view the full article, register now.
Already a subscriber? Click here to view full article